Literature DB >> 6436030

Pharmacokinetics of the selective benzodiazepine antagonist Ro 15-1788 in man.

U Klotz, G Ziegler, I W Reimann.   

Abstract

The pharmacokinetics of the selective benzodiazepine antagonist Ro 15-1788 has been studied in 6 healthy male volunteers following a single intravenous dose of 2.5 mg. The drug was only slightly bound to plasma proteins (40 +/- 8%, mean +/- SD). A negligible amount (less than 0.2% of the dose) of unchanged drug was recovered in urine. Hepatic elimination was rapid, as shown by a short t1/2 of 0.9 +/- 0.2 h, and high total plasma and blood clearances of 691 +/- 216 ml/min and 716 +/- 199 ml/min, respectively. The fast decline of plasma levels from about 60 to 2 ng/ml accounts for the short-lasting reversal of benzodiazepine-induced sedation by Ro 15-1788.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6436030

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  9 in total

1.  Investigation in man of the efficacy of a benzodiazepine antagonist, Ro 15-1788.

Authors:  A Darragh; R Lambe; M Scully; I Brick; C O'Boyle; W W Downe
Journal:  Lancet       Date:  1981-07-04       Impact factor: 79.321

2.  Agonist and antagonist benzodiazepine receptor interaction in vitro.

Authors:  H Möhler; J G Richards
Journal:  Nature       Date:  1981-12-24       Impact factor: 49.962

3.  Tolerance of healthy volunteers to intravenous administration of the benzodiazepine antagonist Ro 15-1788.

Authors:  A Darragh; R Lambe; M Kenny; I Brick
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

4.  RO 15-1788 antagonises the central effects of diazepam in man without altering diazepam bioavailability.

Authors:  A Darragh; R Lambe; M Kenny; I Brick; W Taaffe; C O'Boyle
Journal:  Br J Clin Pharmacol       Date:  1982-11       Impact factor: 4.335

5.  Absence of central effects in man of the benzodiazepine antagonist Ro 15-1788.

Authors:  A Darragh; R Lambe; C O'Boyle; M Kenny; I Brick
Journal:  Psychopharmacology (Berl)       Date:  1983       Impact factor: 4.530

6.  Effect of the benzodiazepine antagonist Ro 15-1788 on flunitrazepam-induced sleep changes.

Authors:  J M Gaillard; R Blois
Journal:  Br J Clin Pharmacol       Date:  1983-05       Impact factor: 4.335

7.  Determination of the benzodiazepine antagonist Ro 15-1788 in plasma by high-performance liquid chromatography with UV detection.

Authors:  U Timm; M Zell
Journal:  Arzneimittelforschung       Date:  1983

8.  Determination of Ro 15-1788, a benzodiazepine antagonist, in human plasma by gas-liquid chromatography with nitrogen-phosphorus detection. Application to single-dose pharmacokinetic studies.

Authors:  D R Abernethy; R M Arendt; P M Lauven; D J Greenblatt
Journal:  Pharmacology       Date:  1983       Impact factor: 2.547

9.  Selective antagonists of benzodiazepines.

Authors:  W Hunkeler; H Möhler; L Pieri; P Polc; E P Bonetti; R Cumin; R Schaffner; W Haefely
Journal:  Nature       Date:  1981-04-09       Impact factor: 49.962

  9 in total
  23 in total

1.  Pharmacokinetic-pharmacodynamic modelling of the interaction between flumazenil and midazolam in volunteers by aperiodic EEG analysis.

Authors:  L T Breimer; A G Burm; M Danhof; P J Hennis; A A Vletter; J W de Voogt; J Spierdijk; J G Bovill
Journal:  Clin Pharmacokinet       Date:  1991-06       Impact factor: 6.447

2.  The effects of the benzodiazepine antagonist Ro 15-1788 on psychophysiological performance and subjective measures in normal subjects.

Authors:  A Higgitt; M Lader; P Fonagy
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

3.  Does the benzodiazepine antagonist Ro 15-1788 antagonize the action of ethanol?

Authors:  U Klotz; G Ziegler; B Rosenkranz; G Mikus
Journal:  Br J Clin Pharmacol       Date:  1986-11       Impact factor: 4.335

4.  Pharmacokinetics of flumazenil in fulminant hepatic failure.

Authors:  C C van der Rijt; R H Drost; S W Schalm; M Schramel
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 5.  Flumazenil. A reappraisal of its pharmacological properties and therapeutic efficacy as a benzodiazepine antagonist.

Authors:  R N Brogden; K L Goa
Journal:  Drugs       Date:  1991-12       Impact factor: 9.546

Review 6.  Flumazenil in dentistry.

Authors:  C Rodrigo
Journal:  Anesth Prog       Date:  1995

7.  Pharmacokinetics of the new benzodiazepine antagonist Ro 15-1788 in man following intravenous and oral administration.

Authors:  G Roncari; W H Ziegler; T W Guentert
Journal:  Br J Clin Pharmacol       Date:  1986-10       Impact factor: 4.335

8.  A quantitative cerebral and whole body autoradiographic study of a intravenously administered benzodiazepine antagonist 3H-Ro 15-1788 in mice.

Authors:  R d'Argy; A Persson; G Sedvall
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

Review 9.  Benzodiazepine antagonists. An update of their role in the emergency care of overdose patients.

Authors:  P J Kulka; P M Lauven
Journal:  Drug Saf       Date:  1992 Sep-Oct       Impact factor: 5.606

Review 10.  Benzodiazepine poisoning. Clinical and pharmacological considerations and treatment.

Authors:  P Gaudreault; J Guay; R L Thivierge; I Verdy
Journal:  Drug Saf       Date:  1991 Jul-Aug       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.